Most notably, elevated hENT1 expression is regarded as a therapeutic biomarker for pancreatic adenocarcinoma and breast cancer in the clinic (Nordh et al., 2014; Pastor-Anglada and Perez-Torras, 2015). Here, SLC29A1 is linked to breast carcinoma.